Plain-English translation of NCT07656116 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase I trial testing VSV-based recombinant oncolytic viruses — a new type of cancer treatment that uses modified viruses to target and attack tumor cells. The study will give participants the medication through injections and carefully monitor how their bodies respond, looking for the right dose and any side effects. This is one of the earliest stages of testing, so researchers are still learning how safe and effective this treatment is.
Many patients with advanced cancers don't benefit from existing treatments or aren't able to receive them. This medication represents a new approach — using specially designed viruses to directly attack cancer cells — and this trial exists to see if it could become a safe and effective option for these patients.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication twice every two weeks as an outpatient. Researchers will carefully monitor your health with blood tests, imaging, and physical exams to see how you respond and watch for side effects. The trial is designed to test different dose levels, starting low and gradually increasing to find the safest and most effective dose — meaning participants enrolled at different times may receive different amounts of the medication.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Enrollment target
~27 participants
Started
January 2026
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yanjie Han, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.